Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 474 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Lupus Erythematosus (Sle) Clear all
Terminated Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

NCT03616912
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 25, 2026, 7:24 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

NCT03920267
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lupus Genetics Studies

NCT00071175
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
3,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jun 25, 2026, 7:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Afimetoran, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Withdrawn Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00382837
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

NCT03556007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

NCT00660881
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

NCT03616964
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jun 25, 2026, 7:24 PM EDT
Recruiting Phase 1 Interventional

US Zamto-cel Autoimmune Diseases

NCT06708845
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
16 Years to 75 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
Interventions
Hydroxychloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Anti-Malarials in Incomplete Lupus Erythematosus

NCT03030118
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo Oral Capsule
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
15 Years to 49 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Great Neck, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 7:24 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)

NCT00418587
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cholecalciferol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Jun 25, 2026, 7:24 PM EDT
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jun 25, 2026, 7:24 PM EDT
Not listed Phase 3 Interventional

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

NCT00053560
View directory record Official record
Conditions
Lupus
Interventions
Prasterone (GL701)
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Jun 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 25, 2026, 7:24 PM EDT
Recruiting No phase listed Observational

CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

NCT06804057
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Blood Collection
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 25, 2026, 7:24 PM EDT